EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

8. When is manufacturer-linked access preferable to an integrated pharmacy partner?

Dose Diligence research deskSection 06 · Page 11 of 22Last updated 17 Nov 2026

Framing: compare the patient journey and clinic workload, not just the medicine price. LillyDirect uses third-party dispensing pharmacies, while NovoCare describes patient registration, payment, fulfilment and delivery support. These are access workflows whose suitability must be tested against the provider’s operating model. (lilly.com)

Put to: Rae McMahan and Adam Fein.
Buyer owner: COO and procurement director.

Why it matters: The relevant question is not whether a channel is universally ‘better’, but which responsibilities the clinic can perform well and which it needs a partner to perform.

A good answer should cover:

  • Patient eligibility, available presentations, payment routes and ongoing terms.
  • Prescription intake, clarification, patient contact, checkout, dispatch and refill responsibilities.
  • What status information the clinic receives and which exceptions remain invisible.
  • Integration costs, patient-choice arrangements and permitted alternative routes.
  • How programme changes are communicated and who helps patients act on them.

Follow-up that tests the answer: “Walk through three cases: no checkout response, a new prescribed dose, and an unaffordable next refill. Where does your system hand responsibility back to us?”

Evidence to request: A side-by-side workflow demonstration with sample status messages and escalation paths. Treat programme descriptions as supplier statements until demonstrated in the proposed clinic workflow.

Expert quote — reserved: ________________________________________

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/faq
Section sources →